A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50

NCT ID: NCT03562923

Last Updated: 2018-06-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 1204 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-31
• Study Completion Date: 2019-06-30

Brief Summary

To compare the efficacy and safety profiles of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder (test product) and ADVAIR DISKUS (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) (reference product) and to show that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Test Product

Test Product, 100/50 mcg, 2 x daily

Group Type: EXPERIMENTAL

Test Product

Intervention Type: DRUG

Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder

Reference Product

Reference Product, 100/50 mcg, 2 x daily

Group Type: ACTIVE_COMPARATOR

Reference Product

Intervention Type: DRUG

ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)

Placebo

Placebo Product 2 x daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo Product

Interventions

Test Product

Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder

Intervention Type: DRUG

Reference Product

ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)

Intervention Type: DRUG

Placebo

Placebo Product

Intervention Type: DRUG

Other Intervention Names

ADVAIR DISKUS

Eligibility Criteria

Inclusion Criteria

• Male or female subjects (≥ 12 years of age) of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control.
• Diagnosed with asthma as defined by the National Asthma Education and Prevention Program (NAEPP) at least 12 weeks prior to screening.
• Pre-bronchodilator FEV1 of ≥40% and ≤85% of the predicted value during the screening visit and on the first day of treatment.
• Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had ≤ 10 pack-years of historical use.
• ≥15% reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
• Able to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
• Able to replace current short-acting β agonists (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits).
• Able to continue the following medications without a significant adjustment of dosage, formulation, dosing interval for the duration of the study, and judged able by the investigator to withhold them for the specified minimum time intervals prior to each clinic visit:

• short-acting forms of theophylline 12 hours
• twice-a-day controlled-release forms of theophylline 24 hours
• once-a-day controlled-release forms of theophylline 36 hours
• Able to discontinue the following medications for the specified minimum time intervals prior to the run-in period and for the remainder of the study:
• oral corticosteroids 1 month
• parenteral corticosteroids 1 month
• oral short-acting β-agonists 12 hours
• Willingness to give their (and in the case of a minor their parent/guardian was able to give) written informed consent to participate in the study.

Exclusion Criteria

• Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year or during the run-in period.
• Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
• Hypersensitivity to any sympathomimetic drug (e.g., salmeterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
• Medication(s) with the potential to affect the course of asthma or to interact with sympathomimetic amines, e.g.:

• β-blockers
• oral decongestants
• benzodiazepines
• digitalis
• phenothiazines
• polycyclic antidepressants
• Monoamine oxidase inhibitors
• Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run-in period.
• Factors (e.g., infirmity, disability or geographic location) that the investigator felt would likely limit the patient's compliance with the study protocol or scheduled clinic visits.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amneal Ireland Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Irshad Haque

Role: STUDY_DIRECTOR

Amneal Pharmaceuticals, LLC

Central Contacts

Irshad Haque

Role: CONTACT

ihaque@amneal.com

631-952-0214

Other Identifiers

AI-FSX-001

Identifier Type: -

Identifier Source: org_study_id